175.99 USD
-0.41 (-0.23%)
174.55 USD
-1.44 (-0.82%)
Taking everything into account, BIIB scores 6 out of 10 in our fundamental rating. BIIB was compared to 530 industry peers in the Biotechnology industry. BIIB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BIIB is valued quite cheap, but it does not seem to be growing. These ratings could make BIIB a good candidate for value investing.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
Each year in the past 5 years BIIB has been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIIB has a better Return On Assets (5.51%) than 92.08% of its industry peers.
BIIB has a Return On Equity of 8.84%. This is amongst the best in the industry. BIIB outperforms 92.26% of its industry peers.
The Return On Invested Capital of BIIB (9.70%) is better than 94.72% of its industry peers.
BIIB had an Average Return On Invested Capital over the past 3 years of 10.57%. This is significantly below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
Looking at the Profit Margin, with a value of 15.98%, BIIB belongs to the top of the industry, outperforming 92.45% of the companies in the same industry.
BIIB's Profit Margin has declined in the last couple of years.
BIIB has a better Operating Margin (28.50%) than 96.60% of its industry peers.
BIIB's Operating Margin has declined in the last couple of years.
BIIB has a better Gross Margin (75.24%) than 83.77% of its industry peers.
In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
BIIB has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.30 indicates that BIIB is not in any danger for bankruptcy at the moment.
BIIB has a better Altman-Z score (3.30) than 69.81% of its industry peers.
The Debt to FCF ratio of BIIB is 2.78, which is a good value as it means it would take BIIB, 2.78 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, BIIB belongs to the top of the industry, outperforming 93.21% of the companies in the same industry.
BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
BIIB has a Debt to Equity ratio of 0.35. This is in the lower half of the industry: BIIB underperforms 68.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.3 |
ROIC/WACC1.17
WACC8.28%
2.3 Liquidity
BIIB has a Current Ratio of 2.72. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
BIIB has a worse Current ratio (2.72) than 68.30% of its industry peers.
BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.04, BIIB is not doing good in the industry: 73.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
The earnings per share for BIIB have been decreasing by -13.31% on average. This is quite bad
Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 0.56% on average per year.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.51, the valuation of BIIB can be described as very reasonable.
Based on the Price/Earnings ratio, BIIB is valued cheaper than 97.55% of the companies in the same industry.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 11.38, which indicates a very decent valuation of BIIB.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 98.11% of the companies in the same industry.
BIIB is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.51 | ||
| Fwd PE | 11.38 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.92% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaply inside the industry as 98.11% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.41 | ||
| EV/EBITDA | 7.72 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
175.99
-0.41 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner Change2.73%
Ins Owners0.14%
Ins Owner Change0.74%
Market Cap25.82B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target183.38 (4.2%)
Short Float %4.5%
Short Ratio3.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)2.19%
PT rev (3m)6.33%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.88%
EPS NY rev (1m)-1.85%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.59%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.51 | ||
| Fwd PE | 11.38 | ||
| P/S | 2.56 | ||
| P/FCF | 11.41 | ||
| P/OCF | 10.52 | ||
| P/B | 1.42 | ||
| P/tB | 10.83 | ||
| EV/EBITDA | 7.72 |
EPS(TTM)16.74
EY9.51%
EPS(NY)15.46
Fwd EY8.78%
FCF(TTM)15.42
FCFY8.76%
OCF(TTM)16.73
OCFY9.5%
SpS68.62
BVpS124.11
TBVpS16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.3 |
F-Score5
WACC8.28%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status of BIOGEN INC (BIIB) stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
How financially healthy is BIOGEN INC?
The financial health rating of BIOGEN INC (BIIB) is 7 / 10.